ArticleAnalytical and bioanalytical chemistry2025
Direct SERS profiling of small extracellular vesicles in cerebrospinal fluid for pediatric medulloblastoma detection and treatment monitoring.
Article in Analytical and bioanalytical chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Gold- or Silver-Nanoparticle SERS Platforms for Plasma-Based Diagnostics and AI-Driven Analysis.Sensors (Basel, Switzerland) · 2026Review
- Extracellular vesicle biomarkers: current status and future perspectives as novel tools in liquid biopsy.Frontiers in immunology · 2026Review
- Cerebrospinal Fluid-Derived Small Extracellular Vesicles May Better Reflect Medulloblastoma Proteomes than Those from Blood Plasma.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Definitive diagnosis of intracranial tumors by less-invasive approaches provides diagnostic information to facilitate personalized treatment decisions and avoid unnecessary invasive biopsy operations. However, it remains challenging, largely due to a lack of reliable molecular biomarkers. Here, we demonstrated that molecular profiles of small extracellular vesicles (sEVs) in cerebrospinal fluid (CSF) decoded by surface-enhanced Raman spectroscopy (SERS) revealed highly specific signatures to detect and accurately discriminate common primary intracranial tumors in children that can be challenging to distinguish using standard-of-care imaging. Specifically, the fabrication of silver nanocube-based three-dimensional SERS substrates enabled the acquisition of highly resolved Raman spectra of sEVs in clinical CSF samples. The development of stacking machine learning frameworks to analyze the Raman data sets unveiled differential vibrational modes and generated high accuracy for diagnosing pediatric medulloblastoma (MB), the most common malignant brain tumor in children, with an area under the receiver operating characteristic curve (AUC(ROC)) of 0.963. Furthermore, we observed high discriminative capacity of our Raman spectral classifier to distinguish MB from other brain tumors (AUC(ROC) = 0.906). Finally, we showed that dynamic analysis of the CSF sEV Raman profiles allowed monitoring of the therapeutic response of MB at the molecular level. Our study holds promise for facilitating precision medicine in brain tumors.
Indexed as
Identifiers
40542894What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.